-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Diabetes increases the risk of depression.
some sugar-lowering drugs, in particular metformin and oxycodone, have been shown to have beneficial effects on depression, but the link between sugar-lowering drugs and depression has not been systematically studied.
a recent study published in Diabetes Care, an authoritative journal in the field of diabetes, researchers teamed up with four Danish-based registries to find out whether 20 widely used oral antisaccharies were associated with a risk of depression.
researchers compared insulin analysis.
study included all patients in Denmark in 2005 and followed them until 2015.
researchers included two different prognostic assessment methods for depressive events: 1) inpatient or outpatient diagnosis of depression in a psychiatric hospital; 2) comprehensive diagnosis of depression or the use of antidepressants.
used the Cox regression model to analyze the data.
the study period, a total of 360,205 subjects used oral anti-sugar drugs and 64,582 subjects used insulin.
continued use of a combination of metformin and metformin can reduce the risk of depression.
was not associated with a decrease in the risk of depression.
other sugar-lowering drugs or insulin were not significantly associated with depression.
result, population-based data show that metformin has benefits for depression.
could be used to guide the treatment of people with type 2 diabetes who are at risk of developing depression.
.
